Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Leonard Shares Significance of the Tazemetostat Approval in Follicular Lymphoma

July 6th 2020

John P. Leonard, MD, discusses the FDA approval of tazemetostat in patients with follicular lymphoma.

Phase 3 Pracinostat Trial Discontinued in Newly Diagnosed AML

July 2nd 2020

Patient recruitment has been discontinued to an interim futility analysis of a phase 3 trial evaluating pracinostat in combination with azacitidine in patients with acute myeloid leukemia demonstrated that it is unlikely to meet the primary end point of overall survival compared with a control arm.

Dr. Ruan on the Utility of Molecular Profiling in Mantle Cell Lymphoma

June 30th 2020

Jia Ruan, MD, PhD, discusses the utility of molecular profiling in mantle cell lymphoma.

FDA Approval Sought for Melphalan Flufenamide in Triple-Class Refractory Myeloma

June 30th 2020

A new drug application has been submitted to the FDA seeking an accelerated approval for melphalan flufenamide in combination with dexamethasone in the treatment of adult patients with triple-refractory multiple myeloma.

Dr. Munshi on the Current Landscape of CAR T-Cell Therapy in Multiple Myeloma

June 30th 2020

Nikhil C. Munshi, MD, discusses the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Dr. Kumar on Stem Cell Mobilization in Multiple Myeloma

June 30th 2020

Shaji K. Kumar, MD, discusses stem cell mobilization multiple myeloma.

Advice for Community Oncologists on Treating HCL

June 30th 2020

Treatments for Relapsed/Refractory HCL in Pipeline

June 30th 2020

The Role of CD22-targeted Immunotoxins in HCL

June 30th 2020

Landscape Change in the Treatment of Relapsed/Refractory HCL

June 30th 2020

Historical Treatment for Relapsed/Refractory HCL

June 30th 2020

When to Not Use Combination and the Need for Bone Marrow Biopsy in HCL

June 30th 2020

Combination First-line Therapy in Hairy Cell Leukemia

June 30th 2020

Determining When to Treat and First-Line Therapy for HCL

June 30th 2020

Differential Diagnosis and Molecular Tests in Identifying HCL

June 30th 2020

Signs and Tests for Diagnosis and Prognosis of HCL

June 30th 2020

Molecular Genetic Changes for Hairy Cell Leukemia

June 30th 2020

Introduction and Epidemiology of Hairy Cell Leukemia

June 30th 2020

Dr. Jacobson on the Next Steps With Axi-Cel in R/R Indolent Non-Hodgkin Lymphoma

June 29th 2020

Caron Jacobson, MD, discusses the next steps with axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Welslau on the Rationale for Rituximab Biosimilar Combination in DLBCL

June 29th 2020

Manfred Welslau, MD, discusses the rationale for investigating the Sandoz rituximab biosimilar, Rixathon, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.